Technology Transfer OfficeView Profile
Center for Technology Transfer and Commercialization of Novosibirsk State University posted this:Technology and equipment for production of ultra-high-molecular-weight polyethylene for medical, structural and energy applicationsThe innovative company (Russia) that cooperates with the university and R&D institutes has developed an UHMWPE production technology (ultra-high-molecular-weight polyethylene) for production of high-strength materials and threads to manufacture implants, porous filters, ropes, armor and materials for aircrafts and ships. The technology is easy to use, products are inexpensive. The company is looking for partners to find market applications for powder and fibers and to license industrial technology.
Universidad de Alcalá-OTRI posted this:Carbosilane dendrimers with a polyphenolic nucleus and their use as antiviralsThe research group in «Dendrimers for biomedical applications» of the University of Alcalá presents carbosilane dendrimers with a polyphenolic nucleus, its obtaining procedure and its uses as antiviral, antibacterial and antifungal agents. The group seeks to reach collaboration agreements, licensing or commercial agreements with technical assistance, with companies from the biotechnology, pharmaceutical and biomedicine sectors in general.
Universidad de Alcalá-OTRI posted this:Carbosilane dendrimers and their use as antiviralsThe research group in "Dendrimers for Biomedical Applications" of the University of Alcalá presents these highly branched macromolecules synthesized from a polyfunctional nucleus, of carbosilane structure and functionalized in its periphery with anionic groups that give the macromolecule a negative net charge. In addition, the invention relates to the use of the dendrimers as an antimicrobial and the process for obtaining them. The group seeks to reach collaboration agreements, licensing or commercial agreements with technical assistance, with companies in the biotechnology, pharmaceutical and biomedicine sectors in general.
Small and Medium Enterprise
Hygea Salud y Nutrición posted this:Nutritional software which makes automatically personalized diets.Vitadieta is a system of Medical Nutrition Therapy, which makes automatically personalized diets for a wide range of goals (lose weight, healthy diet, sports nutrition, pathologies...). The system could be integrate inside a third-party software, or works online. Vitadieta offers functionalities of cross-selling oriented to franchises, recomending product and services of each franchise with the diets.
Research InstituteView Profile
Germans Trias i Pujol Health Sciences Research Institute posted this:Apotransferrin to treat strokeOur group has demonstrated that intravenous administration of apotransferrin strongly reduces the brain damage (up to 75%) in 3 different rat models including both transient and permanent ischemic stroke and improves the neurological impairment (neuroscore 60%) induced by stroke. Thus, this new approach may benefit not only stroke patients who can be treated with current treatment to induce recanalization (transient stroke) but also the 80% of patients who could not benefit from current therapies directed to induce recanalization of the artery (permanent strokes). Results in the preclinical area and some results obtained in serum of stroke patients lead us to think that apotransferrin is a good neuroprotector in the early stages of the ischemic event.
Universidad de Alcalá-OTRI posted this:Metal nanoparticles stabilized with carbosilane dendrons for the treatment of infectious diseases and cancer.The research group in “Dendrimers for biomedical applications” of the University of Alcalá, in collaboration with researchers form the Foundation for Biomedical Research of Gregorio Marañón Hospital in Madrid, present the first example of dendronization of metallic nanoparticles with dendritic systems of ionic carbosilane nature. Also the present invention relates to the method of obtaining these nanoparticles and the use of the mentioned compounds for the treatment of infectious diseases or cancer. The researchers seek for collaboration agreements, licensing or commercial agreements with technical assistance, with companies or institutions from the biomedical sector.
Universidad de Alcalá-OTRI posted this:Mode-Locked pulsed Laser using Saturable AbsorberThe research group in Photonic Engineering from Alcalá University, in collaboration with CSIC, offers a mode-locked pulsed laser whose optical resonator comprises a saturable absorber based on nitrides of group III. The use of this type of materials as saturable absorber allows to achieve a high stability and emission energy without increasing the complexity of the system. Its applications cover areas as diverse as medicine, industry, optical communications and scientific research. The group seeks for companies in these sectors to sign technical cooperation agreements, commercial agreements with technical assistance or patent licensing agreements.
Universidad de Alcalá-OTRI posted this:Double port injector to corneal transplant DMEKThe Reseacrh group in Cell biology of solid tumors and tisular regeneration from Alcala University and the Research group in Cellular Engineering from University from Hospital La Paz, have developed a new injector designed to reduce endotellial damage during the corneal endothelial graft implantation in eye´s anterior chamber. The group is looking for cooperation or commercial agreement with companies manufacturers of sanitary products and medical devices, ophthalmological clinics and hospitals.
RAMOT at Tel Aviv University Ltd. posted this:A novel behavioral bioassay for preclinical testing and characterization of CNS agentsOur team, including zoologists, statisticians, and computer scientists have developed a new hi-res bioassay for preclinical testing and characterization of CNS agents, extracting key animal-centered parameters of behavior via computerized tracking and measurement of free exploration. The features that distinguish our system and method from other existing systems and methods are: elaborate data preparation for analysis and a methodology that secures replicability of results across laboratories, and exposes active management of kinematic variables. Our measured parameters are carefully designed, animal-centered building blocks of behavior. They are selected on the basis of an in-depth understanding of the mouse’s functional world. These quite unexpected and unusual parameters reflect the animal’s cognitive and emotional state and its information processing capacity; therefore they are most prone to be affected by drugs that act on respective CNS structures that mediate these states. Unlike all other existing systems we expose and quantify the rich and highly organized developmental dynamics of self regulated behavioral growth. The dynamics of this process before and after genetic manipulation and/or pharmacological treatment can now be readily measured by our system, articulating the effects of potential CNS drugs on behavioral growth and decay processes. Project ID : 2-2009-11
RAMOT at Tel Aviv University Ltd. posted this:Oral Mucosa-derived Stem Cells: A Unique Population for the Prevention and Treatment of Ischemic Heart FailureStem cells (SC) are considered crucial building blocks for any regenerative strategy. Adult oral mucosa (OM) is a unique source for generating adult pluripotent stem cell (OPSC) populations. This uniqueness consists in the fact that 95% of the OM whole populations in culture (1st – 8th passages) express markers of embryonic and mesenchymal SC. Thus, in contradistinction to known sources which comprise very low numbers of SC, OPSC generation for clinical use is simple and cost effective and does not require cumbersome cost-consuming purification steps. The general objective is to lay the foundation for the development of a variety of products based on the pluripotency and simple and cost effective generation of billions of OPSC. The major aim of the proposed project is to develop a product for the treatment of ischemic heart failure (IHF). This product which will serve as a proof of concept was selected based on medicals needs, market cap and time to market. The specific aims of the proposal are: 1. To develop a cardiac product aimed at treating ischemic heart failure (IHF). The aim is to test the safety and therapeutic effect of OPSC on experimental IHF in a minipig model. 2. To strengthen the intellectual property by fully characterizing the profile of OPSC. The prevalence of IHF continuously increases (1 million new cases every year in the western world) and currently the market cap is estimated in the range of billions. Project ID : 10-2011-260
RAMOT at Tel Aviv University Ltd. posted this:Immunotherapy for Stroke and Cognition in a Cerebral Amyloid Angiopathy Animal ModelCerebral amyloid angiopathy (CAA) is due to amyloid accumulation in the vessel walls leading to hemorrhagic stroke, and cognitive impairment. There are no available treatments to specifically reduce the risk of CAA. In this research we aim to assess brain tissue damage and cognitive impairment resulting from CAA in animal model and to investigate a novel approach to immune therapy. Methods: We have shown that nasal vaccination with a proteosome adjuvant (Protollin) that is well tolerated in humans, decreases amyloid plaques in an Alzheimer’s disease mouse model. It was recently reported that an overexpression of TGF-?1 under the control of an astrocyte promoter GFAP in mice results in CAA. TGF-?1 mice were nasally treated with Protollin on a weekly basis starting at the age of 13 months for three months. Following treatment animals were subjected for MRI and cognition analysis. Results: Here we show that nasal Protollin activates perivascular macrophage and potently decreases vascular amyloid in TGF-?1 mice. Using MRI we found that while PBS treated animals showed a significant enlargement of the lateral ventricles area, Protollin prevents further brain damage and prevents pathological changes in the blood-brain barrier. Vascular risk factors have been found to be associated with vascular dementia. Using an object recognition test and Y-maze, we found significant improvement in cognition with the Protollin treated group. Interpretation :Our study demonstrates that activation of macrophages by Protollin is a novel approach to reduce microhemorrhage, prevent stroke and improve cognition in a model of cerebral amyloid angiopathy. Project ID : 10-2011-259
RAMOT at Tel Aviv University Ltd. posted this:Surface Plasmon Amplification of stimulated emissionSurface Plasmon Amplification of stimulated emission Project ID : 11-2011-127
RAMOT at Tel Aviv University Ltd. posted this:Low energy laser bio-stimulation of bone marrow stem cells for the treatment of myocardial infarctionHeart diseases are the leading cause of death worldwide. Low energy laser (light) irradiation has been shown to have bio-stimulatory beneficial effects on various biological processes in vitro, in vivo and also in clinical trails. We have explored the beneficial effects of light therapy (LT) on stem cells in the bone marrow in order to determine its potential application as cell therapy for the heart post myocardial infarction (MI). Preliminary results have shown that in the infarcted rat heart model the application of LT to the rat bone marrow (BM) in the hind leg 10 min and 4 hrs post MI caused a significant reduction of 79% and 75 % respectively in the scar tissue formed after MI. This is a novel, simple and non-invasive approach to improving heart function after heart attack in patients, and may also serve as a basis for cell therapy of other diseased organs. The fact that LT demonstrated efficacy in scar reduction 4 hours post MI, indicates its clinical relevance to treat patients post MI. Project ID : 2-2011-143
Research & Technology Organization
UNIVERSIDAD DE ALICANTE posted this:Novel self-expanding polyurethane foams intended for inert filling of pleural and other human cavities.The Adhesion and Adhesives Laboratory of the University of Alicante has developed a new polymeric foaming material for in-situ filling and sealing of internal irregular different shaped human cavities, intended for patients suffering chronic pleural cavities and in-field injuries caused by bullets or accidental event leaving open blood vessels. The new foam is composed of two separate liquid components that can be mixed in a two-body syringe in such a way that the foaming time can be modulated for allowing the foam formation at the end of the syringe needle. The new polymeric foam can self-expanded and self-modelated for avoiding complications in open internal cavities caused by infections, blooding, fistulae, dyspnea or sepsis. The new foam is easily applicable, safe for biological tissues, and its use avoid the use of the current aggressive treatments in pleural cavities. It is looking for companies interested in acquiring this technology for its commercial exploitation.